{"nctId":"NCT01951885","briefTitle":"Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD Prevention","startDateStruct":{"date":"2014-07-07","type":"ACTUAL"},"conditions":["Chronic Myelogenous Leukemia","Acute Lymphoblastic Leukemia","Acute Myeloid Leukemia","Acute Biphenotypic Leukemia","Myelodysplastic Syndrome","Myeloproliferative Neoplasm","Non-Hodgkin Lymphoma","Hodgkins Disease","Chronic Lymphocytic Leukemia","Multiple Myeloma"],"count":101,"armGroups":[{"label":"Group A (tacrolimus, methotrexate)","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: tacrolimus","Drug: methotrexate"]},{"label":"Group B (tacrolimus, methotrexate, mycophenolate mofetil)","type":"EXPERIMENTAL","interventionNames":["Drug: tacrolimus","Drug: Mycophenolate mofetil","Drug: Methotrexate (low dose)"]}],"interventions":[{"name":"tacrolimus","otherNames":["FK 506","Prograf"]},{"name":"methotrexate","otherNames":["amethopterin","Folex","methylaminopterin","Mexate","MTX"]},{"name":"Mycophenolate mofetil","otherNames":["Cellcept","MMF"]},{"name":"Methotrexate (low dose)","otherNames":["amethopterin","Folex","methylaminopterin","Mexate","MTX"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients must have one of the following documented diseases:\n\n  * Chronic myelogenous leukemia\n  * Chronic lymphocytic leukemia\n  * Multiple myeloma\n  * Myelodysplasia\n  * Myeloproliferative disorder\n  * Non-Hodgkin's lymphoma\n  * Hodgkin's disease\n  * Acute myelogenous leukemia\n  * Acute lymphoblastic leukemia\n  * Acute biphenotypic leukemia\n* Patients must be undergoing a myeloablative allogeneic hematopoietic cell transplant with one of the following conditioning regimens:\n\n  * Busulfan (≥ 12.8 mg/kg IV or PO) and cyclophosphamide (≥ 120 mg/kg)\n\n    \\--- Busulfan dose may be adjusted according to pharmacokinetics targeting a daily AUC of 5000 μmol-min/L, per institution standard of practice.\n  * Total body irradiation (TBI) (≥ 1200 cGy) and etoposide (60 mg/kg)\n  * TBI (≥ 1200 cGy) and cyclophosphamide (120 mg/kg)\n* Patient must have achieved and be in complete morphologic remission prior to starting conditioning regimen\n* Patient's donor must be a related or unrelated human leukocyte antigen (HLA) 8/8 allele-level match (HLA-A, B, C and DRB1)\n* Adult patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1; pediatric patients must have Lansky score ≥ 60%\n* Patients must have a life expectancy of 100 days\n* Patients must sign written informed consent\n\nExclusion Criteria:\n\n* Patients who have undergone any prior transplant\n* Patients who are seropositive for human immunodeficiency virus (HIV)\n* Patients with any medical illness or concurrent psychiatric illness which, in the investigators' opinion, cannot be adequately controlled with appropriate therapy\n* Patients who are pregnant or lactating","healthyVolunteers":false,"sex":"ALL","maximumAge":"70 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Severe (Grade 3-4) Mucositis Graded According to the World Health Organization (WHO) Grading Scale","description":"Participants (percentage of) will be graded three times per week through day 28 of the study. Incidence will be compared through Wilcoxon rank sum tests.\n\nThe WHO grading scale for mucositis is scaled depending on the severity of mucositis symptoms, with a lower stage associated with a better outcome and greater stages associated with worse outcomes. The staging is as follows:\n\nStage 0: None Stage 1 (mild): Oral soreness, erythema Stage 2 (moderate): Oral erythema, ulcers, solid diet tolerated Stage 3 (severe): Oral ulcers, liquid diet only Stage 4 (life-threatening): Oral alimentation impossible","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"81.6","spread":null},{"groupId":"OG001","value":"57.4","spread":null}]}]}]},{"type":"PRIMARY","title":"Time to Neutrophil Engraftment","description":"The number of days to reach a neutrophil count of greater than or equal to 500/ul for three consecutive laboratory values obtained on different days. The day of engraftment will be the first day of the three consecutive laboratory values.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"15","spread":null}]}]}]},{"type":"PRIMARY","title":"Time to Platelet Engraftment","description":"The number of days to reach a platelet count of greater than or equal to 20,000/ul for three consecutive laboratory values obtained on different days, independent of platelet transfusions the prior 7 days. The day of engraftment will be the first day of the three consecutive laboratory values. For cases of delayed engraftment beyond 28 days, results will be recorded once the participant engrafts.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27","spread":null},{"groupId":"OG001","value":"23","spread":null}]}]}]},{"type":"PRIMARY","title":"Cumulative Incidence of Participants With Acute GVHD","description":"Acute GVHD by grade will be estimated using cumulative incidence methods and compared using the Gray test.\n\nA lower clinical grade and/or stage of GVHD corresponds to a better participant outcome and a higher grade corresponds to a worse participant outcome. Grading is as follows:\n\nGrade 0: No stage 1-4 of any organ Grade 1: Stage 1-2 skin without liver, upper GI, or lower GI involvement. Grade 2: Stage 3 rash and/or stage 1 liver and/or stage 1 upper GI and/or stage 1 lower GI.\n\nGrade 3: Stage 2-3 liver and/or stage 2-3 lower GI, with stage 0-3 skin and/or stage 0-1 upper GI.\n\nGrade 4: Stage 4 skin, liver, or lower GI involvement, with stage 0-1 upper GI.\n\nA greater stage of GVHD involves worsening end-organ involvement and worse participant outcomes based on the skin, liver, lower GI, and upper GI.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"37","spread":null},{"groupId":"OG001","value":"47","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27","spread":null},{"groupId":"OG001","value":"28","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"13","spread":null}]}]}]},{"type":"SECONDARY","title":"Length of Hospitalization","description":"Hospital stay will be compared between patients in groups A and B using the Wilcoxon rank sum test.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31","spread":null},{"groupId":"OG001","value":"27","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Using Total Parenteral Nutrition (TPN) Within 100 Days","description":"TPN use will be compared using the Chi-square test.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"41","spread":null},{"groupId":"OG001","value":"38","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival","description":"Estimated using the Kaplan-Meier method and compared between the 2 groups using the log-rank test.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"71","spread":null},{"groupId":"OG001","value":"72","spread":null}]}]}]},{"type":"SECONDARY","title":"Progression-free Survival","description":"Estimated using the Kaplan-Meier method and compared between the 2 groups using the log-rank test.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"59","spread":null},{"groupId":"OG001","value":"68","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidence of Chronic GVHD","description":"Chronic GVHD will be graded as mild, moderate, or severe based on the National Institutes of Health Consensus Development Project. The type and duration of immunosuppressive treatment given for cGVHD will be recorded. Mild grades are associated with a better participant outcome and severe corresponds to a worse participant outcome. Grading is as follows:\n\nMild: 1 or 2 organs involved with no more than score 1 plus Lung score 0\n\nModerate: 3 or more organs involved with no more than score 1 OR At least 1 organ (not lung) with a score of 2 OR Lung score 1\n\nSevere: At least 1 organ with a score of 3 OR Lung score of 2 or 3\n\nOrgan scores can range from 0 to 3, with 0 being no symptoms on the target organ and a better participant outcome while a score of 3 correlates to severe symptoms on the target organ and worse participant outcomes.\n\nPotential target organs include: skin, mouth, eyes, GI tract, liver, lungs, joint /fascia, and genital tract","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"11","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidence of Chronic GVHD","description":"Chronic GVHD will be graded as mild, moderate, or severe based on the National Institutes of Health Consensus Development Project. The type and duration of immunosuppressive treatment given for cGVHD will be recorded. Mild grades are associated with a better participant outcome and severe corresponds to a worse participant outcome. Grading is as follows:\n\nMild: 1 or 2 organs involved with no more than score 1 plus Lung score 0\n\nModerate: 3 or more organs involved with no more than score 1 OR At least 1 organ (not lung) with a score of 2 OR Lung score 1\n\nSevere: At least 1 organ with a score of 3 OR Lung score of 2 or 3\n\nOrgan scores can range from 0 to 3, with 0 being no symptoms on the target organ and a better participant outcome while a score of 3 correlates to severe symptoms on the target organ and worse participant outcomes.\n\nPotential target organs include: skin, mouth, eyes, GI tract, liver, lungs, joint /fascia, and genital tract","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25","spread":null},{"groupId":"OG001","value":"36","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null},{"groupId":"OG001","value":"23","spread":null}]}]}]},{"type":"SECONDARY","title":"Length of Time on Continuous Infusion Narcotics","description":"Start and stop dates for the need of continuous IV infusion of narcotics for severe mucositis pain will be recorded. Time on IV infusion will be compared between patients in groups A and B using the Wilcoxon rank sum test.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidence of Infection","description":"100-day incidence of infection will be compared using a the Gray test.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"63","spread":null},{"groupId":"OG001","value":"53","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidence of Hepatotoxicity as Measured by Bilirubin","description":"100-day incidence of hepatotoxicity will be compared using a Gray test. Median and range of largest total bilirubin (mg/dL),","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.5","spread":null},{"groupId":"OG001","value":"1.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidence of Hepatotoxicity as Measured by Elevated Liver Enzymes","description":"100-day incidence of hepatotoxicity will be compared using a Gray test. Percentage of patients with elevated Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), and alkaline phosphatase and a 95% confidence interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29","spread":null},{"groupId":"OG001","value":"15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"33","spread":null},{"groupId":"OG001","value":"28","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidence of Hepatotoxicity as Measured by Veno-occlusive Disease (VOD)","description":"100-day incidence of hepatotoxicity will be compared using the Gray test. Percentage of patients with VOD and 95% confidence interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidence of Nephrotoxicity","description":"100-day incidence of nephrotoxicity will be compared using a Chi-squared test. Percentage of patients requiring dialysis and those with elevated creatinine using a 95% confidence interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidence of Pulmonary Toxicity Measured by Pulmonary Hemorrhage","description":"180-day incidence of pulmonary toxicity will be compared using the Gray test. Percentage of patients with pulmonary hemorrhage and 95% confidence interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidence of Pulmonary Toxicity Measured by Pulmonary Edema","description":"180-day incidence of pulmonary toxicity will be compared using the Gray test. Percentage of patients with pulmonary edema and 95% confidence interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidence of Pulmonary Toxicity Measured by Respiratory Failure","description":"180-day incidence of pulmonary toxicity will be compared using the Gray test. Percentage of patients with respiratory failure and 95% confidence interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Chimerism Results","description":"Donor chimerism will be assessed by analysis of single-tandem repeats on whole marrow and in lymphocyte enriched or sorted CD3+ T cells and CD33+ granulocytes. Blood will be obtained for donor chimerism \"Bone Marrow Engraftment analysis\" at approximately 1, 2, 3, 6, 9 and 12 months or as clinically indicated.","classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":13,"n":50},"commonTop":["nausea","diarrhea","vomiting","FATIGUE","hypomagnesemia"]}}}